MASUI Sho

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Division of Integrative Clinical Pharmacology （Shiba-Kyoritsu）

Position

Research Associate/Assistant Professor/Instructor
Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, Kyoto University, Coursework, 2023.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師, 2019.04

Page Top ▲
 

Papers 【 Display / hide 】

  • Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series.

    Masuda T, Funakoshi T, Horimatsu T, Yamamoto S, Matsubara T, Masui S, Nakagawa S, Ikemi Y, Yanagita M, Muto M, Terada T, Yonezawa A

    Cancer chemotherapy and pharmacology  2024.03

    ISSN  0344-5704

  • Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey

    Takayuki Miyamoto, Kazushi Izawa, Sho Masui, Atsue Yamazaki, Yuichi Yamasaki, Tadashi Matsubayashi, Mayuka Shiraki, Hidenori Ohnishi, Junko Yasumura, Kawabe Tomohiro, Takako Miyamae, Tomoyo Matsubara, Naoya Arakawa, Takashi Ishige, Takumi Takizawa, Asami Shimbo, Masaki Shimizu, Naoki Kimura, Yuichi Maeda, Yuta Maruyama, Tomonari Shigemura, Junichi Furuta, Satoshi Sato, Hiroshi Tanaka, Miharu Izumikawa, Masahiro Yamamura, Toshio Hasegawa, Hiroshi Kaneko, Yasuo Nakagishi, Naoko Nakano, Yasunori Iida, Tamaki Nakamura, Hiroyuki Wakiguchi, Takayuki Hoshina, Toshinao Kawai, Kosaku Murakami, Shuji Akizuki, Akio Morinobu, Koichiro Ohmura, Katsuhide Eguchi, Motoshi Sonoda, Masataka Ishimura, Kenji Furuno, Momoko Kashiwado, Masaaki Mori, Kimito Kawahata, Koremasa Hayama, Kumiko Shimoyama, Natsuko Sasaki, Taisuke Ito, Hiroaki Umebayashi, Tae Omori, Seiko Nakamichi, Tomotsune Dohmoto, Yasuyuki Hasegawa, Hisashi Kawashima, Shojiro Watanabe, Yuichiro Taguchi, Haruna Nakaseko, Naomi Iwata, Hiroki Kohno, Taiki Ando, Yasuhiko Ito, Yuko Kataoka, Takako Saeki, Utako Kaneko, Ayako Murase, Seira Hattori, Tomo Nozawa, Kenichi Nishimura, Reiji Nakano, Misa Watanabe, Masato Yashiro, Tomonori Nakamura, Toshihiko Komai, Kentaro Kato, Yoshitaka Honda, Eitaro Hiejima, Atsushi Yonezawa, Kazuhisa Bessho, Satoshi Okada, Osamu Ohara, Junko Takita, Takahiro Yasumi, Ryuta Nishikomori; Japan CAPS working group

    Arthritis Rheumatol  2024.01

    Research paper (scientific journal), Joint Work, Accepted

  • Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.

    Masui S, Yonezawa A, Nakamura M, Onishi A, Hashimoto M, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Yokoyama K, Iwamoto N, Shimada T, Itohara K, Hira D, Nakagawa S, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K

    Biological & pharmaceutical bulletin （Biological and Pharmaceutical Bulletin)  46 （ 8 ） 1112 - 1119 2023

    Research paper (scientific journal), Joint Work, Lead author, Accepted,  ISSN  0918-6158

    　View Summary

    Secondary non-response to infliximab (IFX) occurs in some patients with rheumatoid arthritis (RA). Although therapeutic drug monitoring (TDM) is a useful tool to optimize IFX therapy, it is unclear whether it can help to identify the risk of secondary non-response. This study aimed to explore the utility of serum levels of IFX or other biomarkers to predict IFX discontinuation owing to secondary non-response. A single-center, retrospective study was conducted using the Kyoto University Rheumatoid Arthritis Management Alliance cohort database between 2011 and 2020. Serum IFX levels were measured using liquid chromatography-tandem mass spectrometry. An electrochemiluminescence assay was used to quantify serum levels of tumor necrosis factor-α and interleukin-6 and detect anti-drug antibodies. Eighty-four out of 310 patients were eligible for this study. The cutoff levels of biomarkers were determined by receiver operating characteristic analysis. IFX persistence was similar between groups stratified using IFX levels, tumor necrosis factor-α levels, interleukin-6 levels, and anti-drug antibodies positivity. The group with lower IFX and higher interleukin-6 levels had the worst therapy persistence (p=0.017) and the most frequent disease worsening (90.0%, p<0.001). Evaluating both interleukin-6 and IFX levels, not just IFX alone, enabled us to identify patients at risk of discontinuing IFX treatment. These findings support the utility of measuring IFX and interleukin-6 levels for successful maintenance therapy for RA.

  • N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.

    Masui S, Yonezawa A, Yokoyama K, Iwamoto N, Shimada T, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Nakagawa S, Hira D, Itohara K, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K

    Pharmaceutical research （Pharmaceutical Research)  39 （ 10 ） 2541 - 2554 2022.10

    Research paper (scientific journal), Joint Work, Lead author, Accepted,  ISSN  0724-8741

    　View Summary

    Purpose: Biologics are structurally heterogeneous and can undergo biotransformation in the body. Etanercept (ETN) is a fusion protein composed of a soluble tumor necrosis factor (TNF) receptor and the Fc portion of human immunoglobulin G1. The N-terminus of ETN has a putative sequence cleaved by dipeptidyl peptidase-4 (DPP-4). The purpose of this study was to investigate the biotransformation of ETN in humans and mice and evaluate its effects on functional properties. Methods: An analytical method using liquid chromatography-mass spectrometry (LC–MS/MS) was established. The N-terminal heterogeneity of ETN was assessed in the serum of patients with rheumatoid arthritis or mice receiving ETN. The in vitro N-terminal truncation was explored using recombinant DPP-4. The binding affinity to TNF-α or TNF-β was investigated using an in-house enzyme-linked immunosorbent assay. Results: In the formulations, about 90% of ETN had an intact N-terminus, while the N-terminal truncated form was most abundant in the serum of the patients with rheumatoid arthritis and mice. Recombinant human DPP-4 cleaved two amino acids from the N-terminus of ETN in vitro. Sitagliptin, a DPP-4 inhibitor, inhibited N-terminal truncation both in vivo and in vitro. However, N-terminal truncation did not affect the binding ability to TNF-α or TNF-β and the pharmacokinetics of ETN. ETN biosimilars exhibited similar characteristics to the reference product in vivo and in vitro. Conclusions: ETN undergoes N-terminal truncation in the body, and DPP-4 cleaves exogenous ETN via N-terminal proteolysis. The application of an MS-based assay will detect novel biotransformation of therapeutic proteins.

  • Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.

    Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K

    Biological & pharmaceutical bulletin （Biological and Pharmaceutical Bulletin)  45 （ 3 ） 323 - 332 2022

    Research paper (scientific journal), Lead author, Accepted,  ISSN  0918-6158

    　View Summary

    Infliximab (IFX) has contributed to the treatment of several chronic inflammatory diseases, including Crohn's disease (CD), ulcerative colitis (UC), psoriasis (Pso), and rheumatoid arthritis (RA). However, the loss of response in some patients with long-term IFX therapy has been a major problem. Randomized controlled trials (RCTs) are limited in their short duration and lack of generalizability to the real-world population. We aimed to describe the persistence rates of IFX therapy to estimate its long-term effectiveness in clinical practice. Claims data from the Japan Medical Data Center database from January 2005 to June 2017 were used. The study population was identified based on the International Classification of Diseases, 10th Revision and the Anatomical Therapeutic Chemical Classification System. The 5-year persistence rates of IFX therapy were estimated using the Kaplan-Meier method. Overall, 281, 235, 41, and 222 patients with CD, UC, Pso, and RA, respectively, were selected. The 5-year persistence rates for IFX claims were 62.9, 38.9, 22.1, and 28.1% in patients with CD, UC, Pso, and RA, respectively. Patients with CD and UC administered IFX beyond the median dose had higher persistence rates. In patients with RA, female sex and no prior use of other biologics were associated with longer persistence. In conclusion, IFX persistence rates differed across chronic inflammatory diseases, which did not correspond to the results of the major RCTs. Factors associated with longer IFX persistence were identified in each disease group. Our findings may provide useful information to facilitate the proper use of IFX.

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Measurement of serum Infliximab and Interleukin-6 concentrations predicts continuation of Infliximab treatment in patients with Rheumatoid Arthritis

    Sho Masui, Miyuki Nakamura, Akira Onishi, Motomu Hashimoto, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Kotaro Itohara, Daiki Hira, Shunsaku Nakagawa, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Kazuo Matsubara, Atsushi Yonezawa

    （仮）日本薬学会第144回年会, 

    2024.03
    , 

    Oral presentation (general)

  • バイオシミラーと先行品を用いた抗エタネルセプト抗体測定法の比較

    中山 葵,増井 翔,津田 真弘, 寺田 智祐,米澤 淳

    第17回次世代を担う若手のための医療薬科学シンポジウム, 

    2023.09
    , 

    Oral presentation (general)

  • インフリキシマブのバイオトランスフォーメーションと薬理活性に与える影響

    島田美緒, 米澤淳, 増井翔, 横山琴子, 嶋田崇史, 橋井則貴, 石井明子, 今吉菜月, 津田真弘, 寺田智祐

    医療療薬学フォーラム 2023 第 31 回クリニカルファーマシーシンポジウム, 

    2023.07
    , 

    Poster presentation

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD(INTEGRATIVE CLINICAL PHARMACOLOGY)

    2024

  • SEMINAR(INTEGRATIVE CLINICAL PHARMACOLOGY)

    2024

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2024

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2024

display all >>

Page Top ▲